Shionogi & Co.
All
Newsflash
Article
-
Japanese drugmaker Shionogi to acquire U.S.-based IntraBio for $2 billion to expand rare disease drug business
Japanese drugmaker Shionogi to acquire U.S.-based IntraBio for $2 billion to expand rare disease drug business
-
Japanese drugmaker Shionogi to acquire U.S.-based IntraBio for $2 billion to expand rare disease drug business
Japanese drugmaker Shionogi to acquire U.S.-based IntraBio for $2 billion to expand rare disease drug business
- No data
Shionogi & Co.
Svmuu provides news and information related to Shionogi & Co., as well as real-time data on Shionogi & Co.. We provide in-depth analysis and interpretation of the latest Shionogi & Co. developments, helping investors stay informed about Shionogi & Co. policy updates. Svmuu is your essential tool for keeping up with the latest Shionogi & Co. trends! Here, we’ll join you in keeping a close eye on Shionogi & Co. news and use a clear macro perspective to make sense of the uncertain future of crypto.
24H Trending
-
1
Taiwan Capitalization Weighted Stock Index fell 3.31% from the previous close, currently trading at 38,864.60.
-
2
Hang Seng Index fell 1.52% from its previous close, currently trading at 22,941.09
-
3
CRO (Cronos) Price Pulls Back to $0.04135, Hitting Nearly 365-Day Low
-
4
The Taiwan Capitalization Weighted Stock Index (TAIEX) fell 3.81% from its previous close, currently standing at 38,665.32.
-
5
The Shanghai Composite Index fell 1.05% from its previous close, currently trading at 3,550.32.
-
6
Bloomberg: A-Cap's flagship life insurer seeks to defer policyholder payments while exploring sale
-
7
What is PESA coin? Where to trade and buy PESA coin?
-
8
CoinDesk: Nasdaq futures up nearly 2%; Anthropic indicative quotes briefly 24% higher
-
9
Financial Times: Anthropic Discloses Activation of Measures Under 'Responsible Scaling Policy'
-
10
Bloomberg: Anthropic IPO Benefits SK Telecom's Early Investment, Reports Estimate Returns Around $3 Billion
Markets Today
Recommended Reading

